CARL
Carlsmed, Inc.
Price Chart
Latest Quote
$10.07
+0.09 (+0.90%)
Current Price
| Previous Close | $9.98 |
| Open | $10.12 |
| Day High | $10.12 |
| Day Low | $9.70 |
| Volume | 85,449 |
Stock Information
| Shares Outstanding | 27.18M |
| Total Debt | $17.25M |
| Cash Equivalents | $97.02M |
| Revenue | $56.44M |
| Net Income | $-32.60M |
| Sector | Healthcare |
| Industry | Health Information Services |
| Market Cap | $273.75M |
| EPS (TTM) | $-0.98 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $207.58M |
| Sales | $56.44M |
| Income | $-32.60M |
| Book/sh | $3.39 |
| Cash/sh | $3.57 |
| Employees | 127 |
Financial Ratios
| Quick Ratio | 11.25 |
| Current Ratio | 11.88 |
| Debt/Eq | 18.70 |
Returns & Margins
| ROA | -24.16% |
| ROE | -52.43% |
| Gross Margin | 75.89% |
| Operating Margin | -57.56% |
| Profit Margin | -57.76% |
Ownership
| Insider Ownership | 43.53% |
| Institutional Ownership | 39.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.02 |
| P/S | 4.85 |
| P/B | 2.97 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $18.40 |
Technical Indicators
| SMA20 | $11.19 |
| SMA50 | $10.54 |
| SMA200 | $12.22 |
| RSI | 35.36 |
| ATR | 0.7454 |
| Shares Float | 15.55M |
| Short Float | 12.93% |
| Short Ratio | 5.77 |
| Rel Volume | 0.50 |
Performance History
| Week | -13.34% |
| Month | -10.81% |
| Quarter | -7.27% |
| 6 Months | -20.08% |
| YTD | -13.41% |
| 10 Years | -30.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $10.07 | 85,500 |
| 2026-06-17 | $9.98 | 151,300 |
| 2026-06-16 | $10.57 | 336,100 |
| 2026-06-15 | $11.03 | 92,800 |
| 2026-06-12 | $11.42 | 55,700 |
| 2026-06-11 | $11.62 | 47,500 |
| 2026-06-10 | $11.45 | 80,800 |
| 2026-06-09 | $11.29 | 73,600 |
| 2026-06-08 | $11.05 | 46,600 |
| 2026-06-05 | $11.07 | 79,200 |
| 2026-06-04 | $11.14 | 114,500 |
| 2026-06-03 | $10.20 | 138,500 |
| 2026-06-02 | $10.17 | 147,500 |
| 2026-06-01 | $11.10 | 173,500 |
| 2026-05-29 | $11.42 | 103,900 |
| 2026-05-28 | $11.81 | 95,200 |
| 2026-05-27 | $11.72 | 181,200 |
| 2026-05-26 | $11.89 | 239,400 |
| 2026-05-22 | $12.11 | 335,300 |
| 2026-05-21 | $12.65 | 871,900 |
| 2026-05-20 | $11.77 | 286,800 |
| 2026-05-19 | $11.29 | 482,400 |
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
đ° Latest News
Wall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This High?
Zacks âĸ 2026-05-25T13:55:03Z
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-05-22T13:40:02Z
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet
Zacks âĸ 2026-05-08T13:55:05Z
Here's What Analysts Are Forecasting For Carlsmed, Inc. (NASDAQ:CARL) After Its First-Quarter Results
Simply Wall St. âĸ 2026-05-07T19:34:39Z
Carlsmed Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-05T23:43:18Z
Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-05T22:05:05Z
Carlsmed (CARL) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-05T21:53:50Z
Carlsmed Showcases Personalized Spine Fusion Gains, Cervical Expansion and Medicare Tailwinds at Needham Conf
MarketBeat âĸ 2026-04-13T18:43:26Z
Carlsmed Unveils Personalized Spine Platform, Targets $70M-$75.5M 2025 Revenue at Conference
MarketBeat âĸ 2026-03-07T13:32:00Z
Carlsmed Q4 Earnings Call Highlights
MarketBeat âĸ 2026-02-26T05:07:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Reconciled Cost Of Revenue | $12,471,000 | $7,117,000 | $3,875,000 |
| Cost Of Revenue | $12,471,000 | $7,117,000 | $3,875,000 |
| Total Revenue | $50,511,000 | $27,165,000 | $13,778,000 |
| Operating Revenue | $50,511,000 | $27,165,000 | $13,778,000 |
| Expenses | |||
| Interest Expense | $1,430,000 | $1,321,000 | $641,000 |
| Total Expenses | $81,085,000 | $51,287,000 | $32,369,000 |
| Other Income Expense | $-328,000 | $-144,000 | - |
| Net Non Operating Interest Income Expense | $1,268,000 | $9,000 | $-307,000 |
| Interest Expense Non Operating | $1,430,000 | $1,321,000 | $641,000 |
| Operating Expense | $68,614,000 | $44,170,000 | $28,494,000 |
| Selling And Marketing Expense | $35,027,000 | $21,472,000 | $15,101,000 |
| General And Administrative Expense | $16,568,000 | $8,394,000 | $5,998,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-29,634,000 | $-24,257,000 | $-18,898,000 |
| Net Interest Income | $1,268,000 | $9,000 | $-307,000 |
| Interest Income | $2,698,000 | $1,330,000 | $334,000 |
| Normalized Income | $-29,306,000 | $-24,113,000 | $-18,898,000 |
| Net Income From Continuing And Discontinued Operation | $-29,634,000 | $-24,257,000 | $-18,898,000 |
| Total Operating Income As Reported | $-30,574,000 | $-24,122,000 | $-18,591,000 |
| Net Income Common Stockholders | $-30,218,000 | $-24,849,000 | $-18,898,000 |
| Net Income | $-29,634,000 | $-24,257,000 | $-18,898,000 |
| Net Income Including Noncontrolling Interests | $-29,634,000 | $-24,257,000 | $-18,898,000 |
| Net Income Continuous Operations | $-29,634,000 | $-24,257,000 | $-18,898,000 |
| Pretax Income | $-29,634,000 | $-24,257,000 | $-18,898,000 |
| Interest Income Non Operating | $2,698,000 | $1,330,000 | $334,000 |
| Operating Income | $-30,574,000 | $-24,122,000 | $-18,591,000 |
| Gross Profit | $38,040,000 | $20,048,000 | $9,903,000 |
| Per Share | |||
| Diluted EPS | $-2.12 | $-6.11 | $-4.25 |
| Basic EPS | $-2.12 | $-6.11 | $-4.25 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,595,000 | $-22,647,000 | $-18,121,000 |
| Total Unusual Items | $-328,000 | $-144,000 | - |
| Total Unusual Items Excluding Goodwill | $-328,000 | $-144,000 | - |
| Reconciled Depreciation | $281,000 | $145,000 | $136,000 |
| EBITDA (Bullshit earnings) | $-27,923,000 | $-22,791,000 | $-18,121,000 |
| EBIT | $-28,204,000 | $-22,936,000 | $-18,257,000 |
| Diluted Average Shares | $14,221,991 | $4,066,395 | $4,445,384 |
| Basic Average Shares | $14,221,991 | $4,066,395 | $4,445,384 |
| Diluted NI Availto Com Stockholders | $-30,218,000 | $-24,849,000 | $-18,898,000 |
| Preferred Stock Dividends | $584,000 | $592,000 | - |
| Gain On Sale Of Security | $-328,000 | $-144,000 | - |
| Research And Development | $17,019,000 | $14,304,000 | $7,395,000 |
| Selling General And Administration | $51,595,000 | $29,866,000 | $21,099,000 |
| Other Gand A | $16,568,000 | $8,394,000 | $5,998,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $98,869,000 | $-70,630,000 | $-46,130,000 |
| Total Assets | $130,120,000 | $51,824,000 | $14,024,000 |
| Total Non Current Assets | $3,447,000 | $2,473,000 | $2,259,000 |
| Other Non Current Assets | $134,000 | $569,000 | $15,000 |
| Current Assets | $126,673,000 | $49,351,000 | $11,765,000 |
| Other Current Assets | $3,573,000 | $1,365,000 | $653,000 |
| Restricted Cash | $100,000 | $100,000 | $150,000 |
| Inventory | $1,845,000 | $995,000 | $575,000 |
| Receivables | $11,362,000 | $6,766,000 | $3,165,000 |
| Accounts Receivable | $11,362,000 | $6,766,000 | $3,165,000 |
| Allowance For Doubtful Accounts Receivable | $-1,653,000 | $-1,239,000 | $-871,000 |
| Gross Accounts Receivable | $13,015,000 | $8,005,000 | $4,036,000 |
| Cash Cash Equivalents And Short Term Investments | $109,793,000 | $40,125,000 | $7,222,000 |
| Cash And Cash Equivalents | $85,793,000 | $40,125,000 | $7,222,000 |
| Debt | |||
| Total Debt | $17,414,000 | $17,180,000 | $11,387,000 |
| Long Term Debt And Capital Lease Obligation | $16,662,000 | $16,731,000 | $9,239,000 |
| Long Term Debt | $15,346,000 | $15,414,000 | $7,473,000 |
| Current Debt And Capital Lease Obligation | $752,000 | $449,000 | $2,148,000 |
| Net Debt | - | - | $2,089,000 |
| Current Debt | - | - | $1,838,000 |
| Other Current Borrowings | - | - | $1,838,000 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $31,251,000 | $122,454,000 | $60,154,000 |
| Total Non Current Liabilities Net Minority Interest | $16,971,000 | $113,636,000 | $52,714,000 |
| Other Non Current Liabilities | $309,000 | $222,000 | $96,000 |
| Derivative Product Liabilities | $0 | $457,000 | $0 |
| Current Liabilities | $14,280,000 | $8,818,000 | $7,440,000 |
| Payables And Accrued Expenses | $7,698,000 | $4,987,000 | $3,061,000 |
| Payables | $4,481,000 | $2,412,000 | $1,694,000 |
| Accounts Payable | $4,481,000 | $2,412,000 | $1,694,000 |
| Equity | |||
| Common Stock Equity | $98,869,000 | $-70,630,000 | $-46,130,000 |
| Total Equity Gross Minority Interest | $98,869,000 | $-70,630,000 | $-46,130,000 |
| Stockholders Equity | $98,869,000 | $-70,630,000 | $-46,130,000 |
| Retained Earnings | $-100,805,000 | $-71,171,000 | $-46,914,000 |
| Preferred Securities Outside Stock Equity | $0 | $96,226,000 | $43,379,000 |
| Other | |||
| Ordinary Shares Number | $26,664,243 | $26,516,274 | $26,516,274 |
| Share Issued | $26,664,243 | $26,516,274 | $26,516,274 |
| Tangible Book Value | $98,869,000 | $-70,630,000 | $-46,130,000 |
| Invested Capital | $114,215,000 | $-55,216,000 | $-36,819,000 |
| Working Capital | $112,393,000 | $40,533,000 | $4,325,000 |
| Capital Lease Obligations | $2,068,000 | $1,766,000 | $2,076,000 |
| Total Capitalization | $114,215,000 | $-55,216,000 | $-38,657,000 |
| Additional Paid In Capital | $199,674,000 | $541,000 | $784,000 |
| Capital Stock | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | - |
| Long Term Capital Lease Obligation | $1,316,000 | $1,317,000 | $1,766,000 |
| Current Capital Lease Obligation | $752,000 | $449,000 | $310,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,830,000 | $3,382,000 | $2,231,000 |
| Current Accrued Expenses | $3,217,000 | $2,575,000 | $1,367,000 |
| Net PPE | $3,313,000 | $1,904,000 | $2,244,000 |
| Accumulated Depreciation | $-526,000 | $-399,000 | $-254,000 |
| Gross PPE | $3,839,000 | $2,303,000 | $2,498,000 |
| Leases | $355,000 | $80,000 | $80,000 |
| Construction In Progress | $524,000 | $0 | - |
| Other Properties | $1,826,000 | $1,644,000 | $2,019,000 |
| Machinery Furniture Equipment | $1,134,000 | $579,000 | $399,000 |
| Properties | $0 | $0 | $0 |
| Finished Goods | $1,788,000 | $595,000 | $276,000 |
| Work In Process | $57,000 | $400,000 | $299,000 |
| Other Short Term Investments | $24,000,000 | $0 | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-30,334,000 | $-25,646,000 | $-17,615,000 |
| Operating Activities | |||
| Operating Cash Flow | $-28,977,000 | $-25,466,000 | $-17,480,000 |
| Cash Flow From Continuing Operating Activities | $-28,977,000 | $-25,466,000 | $-17,480,000 |
| Operating Gains Losses | $328,000 | $144,000 | - |
| Investing Activities | |||
| Capital Expenditure | $-1,357,000 | $-180,000 | $-135,000 |
| Investing Cash Flow | $-25,483,000 | $-180,000 | $-135,000 |
| Cash Flow From Continuing Investing Activities | $-25,483,000 | $-180,000 | $-135,000 |
| Net Other Investing Changes | $-126,000 | - | - |
| Capital Expenditure Reported | $-715,000 | $0 | - |
| Financing Activities | |||
| Issuance Of Capital Stock | $105,384,000 | $52,255,000 | $0 |
| Financing Cash Flow | $100,128,000 | $58,499,000 | $3,180,000 |
| Cash Flow From Continuing Financing Activities | $100,128,000 | $58,499,000 | $3,180,000 |
| Net Other Financing Charges | $-5,461,000 | - | - |
| Net Preferred Stock Issuance | $11,919,000 | $52,255,000 | $0 |
| Preferred Stock Issuance | $11,919,000 | $52,255,000 | $0 |
| Net Common Stock Issuance | $93,465,000 | $0 | - |
| Common Stock Issuance | $93,465,000 | $0 | - |
| Other | |||
| Issuance Of Debt | $0 | $6,210,000 | $3,125,000 |
| Interest Paid Supplemental Data | $1,198,000 | $1,115,000 | $515,000 |
| End Cash Position | $85,893,000 | $40,225,000 | $7,372,000 |
| Beginning Cash Position | $40,225,000 | $7,372,000 | $21,807,000 |
| Changes In Cash | $45,668,000 | $32,853,000 | $-14,435,000 |
| Proceeds From Stock Option Exercised | $205,000 | $34,000 | $55,000 |
| Net Issuance Payments Of Debt | $0 | $6,210,000 | $3,125,000 |
| Net Long Term Debt Issuance | $0 | $6,210,000 | $3,125,000 |
| Long Term Debt Issuance | $0 | $6,210,000 | $3,125,000 |
| Net Investment Purchase And Sale | $-24,000,000 | $0 | - |
| Purchase Of Investment | $-24,000,000 | $0 | - |
| Net PPE Purchase And Sale | $-642,000 | $-180,000 | $-135,000 |
| Purchase Of PPE | $-642,000 | $-180,000 | $-135,000 |
| Change In Working Capital | $-4,891,000 | $-4,078,000 | $-893,000 |
| Change In Other Current Liabilities | $-290,000 | $-310,000 | $-558,000 |
| Change In Payables And Accrued Expense | $5,440,000 | $2,719,000 | $3,138,000 |
| Change In Accrued Expense | $3,117,000 | $2,422,000 | $2,195,000 |
| Change In Payable | $2,323,000 | $297,000 | $943,000 |
| Change In Account Payable | $2,323,000 | $297,000 | $943,000 |
| Change In Prepaid Assets | $-2,342,000 | $-720,000 | $-128,000 |
| Change In Inventory | $-2,689,000 | $-1,798,000 | $-914,000 |
| Change In Receivables | $-5,010,000 | $-3,969,000 | $-2,431,000 |
| Changes In Account Receivables | $-5,010,000 | $-3,969,000 | $-2,431,000 |
| Other Non Cash Items | $759,000 | $581,000 | $549,000 |
| Stock Based Compensation | $1,927,000 | $253,000 | $115,000 |
| Provisionand Write Offof Assets | $414,000 | $368,000 | $871,000 |
| Asset Impairment Charge | $1,839,000 | $1,378,000 | $640,000 |
| Depreciation Amortization Depletion | $281,000 | $145,000 | $136,000 |
| Depreciation And Amortization | $281,000 | $145,000 | $136,000 |
| Gain Loss On Investment Securities | $328,000 | $144,000 | - |
| Net Income From Continuing Operations | $-29,634,000 | $-24,257,000 | $-18,898,000 |
Fetched: 2026-06-17